Clinical and metabolic effects of Gynodian-depot in vegetoneurotic disorders following removal of uterine myoma in menopausal patients

E M Vikhliaeva, E.V. Uvarovа, I.S. Talina
In: European Journal of Obstetrics & Gynecology and Reproductive Biology · 1983 · vol. 16(3) , pp. 213–225 · doi:10.1016/0028-2243(83)90101-6 · PMID:6229431 · W1968198845
article OA: bronze CC0
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-08-14 ⓘ

Gynodian-depot injections effectively alleviated vegetoneurotic, psychoemotional, and metabolic-endocrine disorders in menopausal patients following hysterectomy for uterine myoma with minimal side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Clinical and metabolic effects of depot-injections of estradiol valerianate-dehydroepiandrosterone enanthate at a 1:50 ratio (Gynodian-depot) in the treatment of severe clinical manifestations of the vegetoneurotic syndrome were evaluated in menopuasal patients after hysterectomy for uterine myoma. Favourable comprehensive effects of the drug were noted, which in most patients contributed to the elimination or significant alleviation of major vegetoneurotic, psychoemotional and metabolic-endocrine disorders. An effective combination of the estrogenic and androgenic hormonal components and their ratios, coupled with very insignificant side-effects, is an important advantage of the drug, permitting its large-scale use for the control of menopausal complications, particularly after surgery for a uterine tumour.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (24)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK